Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Since Retatrutide is not approved for general consumer use in the UK, it is illegal to sell, supply, or use it for non-research purposes
Our approach is centered on supporting you with the highest standard of care every step of the way
Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
CJC-1295 is typically dosed at 1-2 mg per week
The former Calibrate health coach suggested another factor in the startup's strategy: what insurance companies were willing to pay for
US$ 22.44
US$ 24.72
US$ 27.78
US$ 26.90
US$ 26.19
